In today’s briefing:
- Gemini at Work 2026. Impressive Enterprise AI Strategy Is Revealed. Key Takeaways & Full Transcript
- Micron sells AI memory before the year starts, and each bit takes three times the wafer
- U.S. IPO Recap Week of 10/9/2026
- AkzoNobel / Axalta: EU Remedies Take Shape
- IPO Rating: Iambic Therapeutics, Inc.
- Base Oils and Lubricants: Weekly Global Market Review – 9 Oct ’26
- Oil futures: Crude eases as Trump rules out pre-election strike on Iran
- Roundhill Memory ETF (DRAM US): Over-Punished, Not Broken – We Stay Long but Trim Our TP to US$70
- Specificity (SPCF US): Synthetic Expert Call Transcript (12 Oct 2026)
- Iambic Therapeutics (IAM) Eyes $150 Million IPO to Advance AI-Designed Cancer Therapies
Gemini at Work 2026. Impressive Enterprise AI Strategy Is Revealed. Key Takeaways & Full Transcript
- Google’s latest frontier model, Argon, delivers frontier performance and complex workflows across knowledge work, real-world software engineering, and cybersecurity defense.
- The Chrome team (3 billion users) has been using Argon to refactor features that span millions of lines of code. Normally, this would take months. They’ve done it in weeks
- Gemini is the agent. The model underneath is a separate choice, and it is yours. From Argon at the frontier to Flash for speed and to the latest Claude models.
Micron sells AI memory before the year starts, and each bit takes three times the wafer
- Micron, one of three companies that make the stacked memory beside AI chips, commits most of each year’s supply of it before that year starts.
- By Micron’s own account, each unit of it uses about three times the silicon of ordinary computer memory.
- So while AI memory grows faster than the rest, it takes silicon away from the ordinary memory in phones, laptops and servers, and keeps that short too.
U.S. IPO Recap Week of 10/9/2026
- One qualifying IPO priced and began trading this week: TRex Bio raised $116.7 million.
- It priced at the low end of its range, opened below issue, recovered to a double-digit intraday premium and closed exactly at the $14.00 issue price.
- The result kept the financing window open for biotech, but it did not demonstrate broad risk appetite.
AkzoNobel / Axalta: EU Remedies Take Shape
- EU clearance appears increasingly likely following reports of a proposed vehicle-refinish divestiture, although the scope of the remedy, disposal proceeds and impact on synergies remain undisclosed.
- Our revised synergy DCF values the $600m annual savings programme at €3.61bn after a 25% execution-risk discount. Losing $50–100m of annual savings would reduce that valuation by €0.33–0.66bn.
- AkzoNobel’s Asian disposals have secured attractive multiples, but the merger spread is just 0.2%. We see insufficient compensation for the remaining risks and would not initiate an arbitrage position.
IPO Rating: Iambic Therapeutics, Inc.
- ✓ IPO Prophet Rating: 7.83/10 🏦 Deal Quality & Underwriters: 8.35/10 Iambic Therapeutics is offering 9.38 million all-primary shares at $15.00–$17.00, representing approximately $150 million at the midpoint and an implied market capitalization of roughly $758 million.
- The Nasdaq transaction is expected to price October 15 under the ticker IAM.
- J.P. Morgan, Jefferies, BofA Securities and Citigroup provide a strong healthcare-focused underwriting syndicate capable of reaching both specialist biotechnology investors and broader institutions.
Base Oils and Lubricants: Weekly Global Market Review – 9 Oct ’26
-
Spare base oils supply is thin across major regions, leaving little room to absorb disruption from storms, outages or maintenance
-
Asia cleared a swathe of supply in the third quarter, leaving it balanced to tight with less room to cover other markets.
-
Singapore’s exports fell for a second week, a slowdown that would further limit Asia’s spare supply if it continues as seasonal demand firms.
Oil futures: Crude eases as Trump rules out pre-election strike on Iran
- Crude oil futures eased slightly on Friday after US President Donald Trump ruled out immediate attacks on Iran, while Hurricane Isaias has taken a more easterly direction and away from the Louisiana onshore oil hub.
- Front-month Dec26 ICE Brent futures were 0.2% lower at $104.09/b (2101 BST), while Nov26 NYMEX WTI was at $91.38/b , down 0.1% versus Thursday’s settle.
- President Donald Trump said on Thursday the US would not attack Iran before the midterm elections, tempering rising crude oil prices after several US media reports had flagged that renewed military strikes were looking imminent.
Roundhill Memory ETF (DRAM US): Over-Punished, Not Broken – We Stay Long but Trim Our TP to US$70
- Sold on fear, not numbers. Micron beat FQ4 (revenue US$54.2bn vs US$51.0bn consensus) and guided higher; Samsung printed a record ₩107.4tn Q3 profit. Both stocks fell on the news.
- Memory chip pricing is intact. TrendForce still sees Q4 contract prices up 10–15% for conventional DRAM and 15–20% for NAND. Micron’s CEO sees demand above supply through 2028.
- Cheap valuations. DRAM trades on ~7.0x forward earnings; Micron on 7.9x our FY27E EPS, SK Hynix 6.2x, Samsung 5.0x.
Specificity (SPCF US): Synthetic Expert Call Transcript (12 Oct 2026)
- PickPocket’s proprietary MAID (Mobile Advertising Identifier) and buyer-intent tech provide a distinct performance lift for local and mid-market accounts, but scaling beyond $1.09 million in annual baseline revenue is constrained by raw data licensing costs and high client churn in lower-tier SMB segments.
- The company’s capital structure remains acutely distressed, burdened by a defaulted $1.00 million related-party note, repeated 2026 SEC filing delays, and an active going-concern audit warning that severely limits non-dilutive financing options.
- A turnaround or strategic sale hinges on monetizing the PickPocket platform and speed-to-lead IP through white-label agency partnerships (Tradigital Partners) or an asset sale to a larger ad-tech aggregator, given the high key-person dependency on CEO Jason Wood.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
Iambic Therapeutics (IAM) Eyes $150 Million IPO to Advance AI-Designed Cancer Therapies
- Iambic Therapeutics (IAM) , a San Diego-based biotechnology company combining artificial intelligence with automated laboratory research, is preparing to offer 9.375 million shares on the Nasdaq Global Select Market at $15–$17 per share .
- At the $16 midpoint , the offering would raise $150 million in gross proceeds and imply a post-offering market capitalization of approximately $758.4 million .
- J.P. Morgan, Jefferies, BofA Securities, and Citigroup are the joint book-running managers. The preliminary prospectus does not specify a final pricing or trading date.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
